OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy
Tomoo Sato, Masahiro Nagai, Osamu Watanabe, et al.
Journal of Neurology (2024) Vol. 271, Iss. 6, pp. 3471-3485
Open Access | Times Cited: 6
Tomoo Sato, Masahiro Nagai, Osamu Watanabe, et al.
Journal of Neurology (2024) Vol. 271, Iss. 6, pp. 3471-3485
Open Access | Times Cited: 6
Showing 6 citing articles:
Human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis and multiple sclerosis: Viral strategies and their implications
Makoto Nakashima, Yoshihisa Yamano
Clinical and Experimental Neuroimmunology (2025)
Closed Access | Times Cited: 1
Makoto Nakashima, Yoshihisa Yamano
Clinical and Experimental Neuroimmunology (2025)
Closed Access | Times Cited: 1
Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors
Koichi Jinushi, Takuro Saito, Koji Kurose, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 4, pp. e010634-e010634
Open Access
Koichi Jinushi, Takuro Saito, Koji Kurose, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 4, pp. e010634-e010634
Open Access
Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature
Genevieve S. Silva, Ellen J. Kim, Stefan K. Barta, et al.
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 9, pp. 819-827
Closed Access | Times Cited: 3
Genevieve S. Silva, Ellen J. Kim, Stefan K. Barta, et al.
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 9, pp. 819-827
Closed Access | Times Cited: 3
Current State of Therapeutics for HTLV-1
T. Wang, Ashley Hirons, Marcel Doerflinger, et al.
Viruses (2024) Vol. 16, Iss. 10, pp. 1616-1616
Open Access | Times Cited: 3
T. Wang, Ashley Hirons, Marcel Doerflinger, et al.
Viruses (2024) Vol. 16, Iss. 10, pp. 1616-1616
Open Access | Times Cited: 3
Non-cancerous complications in HTLV-1 carriers
Akihiro Ohmoto, Shigeo Fuji
Expert Review of Anti-infective Therapy (2024) Vol. 22, Iss. 5, pp. 307-316
Closed Access
Akihiro Ohmoto, Shigeo Fuji
Expert Review of Anti-infective Therapy (2024) Vol. 22, Iss. 5, pp. 307-316
Closed Access
B‐cell depletion limits HTLV‐1‐infected T‐cell expansion and ameliorate HTLV‐1‐associated myelopathy
Aowei Lv, Yaofeng Fang, Xiao-Hong Lin, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 10, pp. 2756-2768
Open Access
Aowei Lv, Yaofeng Fang, Xiao-Hong Lin, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 10, pp. 2756-2768
Open Access
